Health-related quality of life (HRQoL) during treatment with enasidenib (ENA) plus azacitidine (AZA) in patients with newly diagnosed mutant IDH2 (m IDH2) acute myeloid leukemia (AML) not eligible for intensive chemotherapy (IC)

Détails bibliographiques
Auteurs principaux:	DiNardo, CD, Dohner, H, Zeidan, AM, Schuh, AC, Vyas, P, Stein, EM, Wei, AH, de Botton, S, Chen, C, Lord-Bessen, J, Martin-Regueira, P, Lersch, F, Gong, J, Guo, S, Shi, L, Montesinos, P
Format:	Conference item
Langue:	English
Publié:	American Society of Hematology 2021

Documents similaires